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Strengths and limitations of this study
 ► This is the first randomised clinical trial on operative 
versus non-operative treatment of proximal ham-
string avulsions.
 ► The multicentre design will support external validity 
and implementation.
 ► The treatment outcome will be assessed with 
a hamstring-specific validated Patient Related 
Outcome Meassure (PROM), objective functional 
tests and imaging.
 ► Owing to the type of interventions, blinding of the 
patients and treatment providers is not possible.
AbStrACt
Introduction The treatment of proximal hamstring 
avulsions is controversial. While several trials have 
investigated the outcome for patients treated surgically, 
there is today no prospective trial comparing operative 
treatment with non-operative treatment. This protocol 
describes the design for the proximal hamstring avulsion 
clinical trial (PHACT)—the first randomised controlled trial 
of operative versus non-operative treatment for proximal 
hamstring avulsions.
Methods and analysis PHACT is a multicentre 
randomised controlled trial conducted across Sweden, 
Norway and Finland. Eligible patients (60 participants/
treatment arm) with a proximal hamstring avulsion of 
at least two of three tendons will be randomised to 
either operative or non-operative treatment. Participants 
allocated to surgery will undergo reinsertion of the tendons 
with suture anchors. The rehabilitation programme will 
be the same for both treatment groups. When patient 
or surgeon equipoise for treatment alternatives cannot 
be reached and randomisation therefore is not possible, 
patients will be invited to participate in a parallel 
observational non-randomised cohort. The primary 
outcome will be the patient-reported outcome measure 
Perth hamstring assessment tool at 24 months. Secondary 
outcomes include the Lower Extremity Functional Score, 
physical performance and muscle strength tests, patient 
satisfaction and MR imaging. Data analysis will be blinded 
and intention-to-treat analysis will be preformed.
Ethics and dissemination Ethical approval has been 
granted by the Ethical Committee of Uppsala University 
(DNR: 2017–170) and by the Norwegian ethical board 
(REC: 2017/1911). The study will be conducted in 
agreement with the Helsinki declaration. The findings will 
be disseminated in peer-reviewed publications.
trial registration number NCT03311997
IntroduCtIon
The treatment of proximal hamstring avul-
sions is controversial. The literature suggests 
that surgical treatment is the treatment of 
choice. For example, in a recent systematic 
review by Bodendorfer et al,1 it is claimed that 
surgically treated patients have better results in 
psychometric scores, functional and strength 
tests than non-surgically treated patients. 
However, existing literature may be biased. 
The studies conducted so far are mainly retro-
spective case series1 2 and have only occasion-
ally used validated outcome measures, such as 
Harris Hip Score3 and Lower Extremity Func-
tional Scale (LEFS).3–5 The Perth hamstring 
assessment tool (PHAT)6 is designed and vali-
dated for follow-up of patients with hamstring 
avulsion,6 but was only recently developed.
Bodendorfer et al1 only found 28 non-sur-
gical-treated patients compared with 767 
surgical-treated patients to include in their 
review, suggesting a publication bias in the 
existing literature and providing limited 
power for comparisons between the surgi-
cally and non-surgically treated patients. In 
the light of the apparent lack of comparative 
studies, one needs to be aware of surgical 
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complication rates when suggesting operative treatment. 
With a reported aggregated complication rate as high as 
23% in the surgically treated group,1 surgery cannot be 
considered harmless.
The aim of this prospective, multicentre, randomised 
controlled trial is to provide reliable evidence on how to 
treat physically active patients, 30–70 years of age, with 
proximal hamstring avulsions. We will use PHAT6 at 24 
months post-treatment allocation as our primary outcome 
measure.
MEthodS And AnAlySIS
Study design and setting
The proximal hamstring avulsion clinical trial is a multi-
centre, prospective, preference-tolerant, randomised, 
controlled, non-inferiority trial with two treatment arms. 
The protocol was developed in accordance with Standard 
Protocol Items: Recommendations for Interventional 
Trials and Template for Intervention Description and 
Replication statements.7 8
The study is conducted in cooperation with Swedish 
Orthopaedic Trauma Society and has 11 study sites at 
orthopaedic departments across Sweden, Norway and 
Finland. Inclusion started in September 2017 and recruit-
ment is expected to finalise in 2021, which would allow 
for read-out of the primary endpoint in 2023.
recruitment strategy
Patients with proximal hamstring avulsions that are diag-
nosed or referred to the orthopaedic department at 1 
of the 11 hospitals will be screened for participation in 
the study. Eligible patients are invited to participate and 
provided with oral and written information. Thereafter, 
patients are asked to sign a written informed consent 
statement before any study procedure occurs.
Patients
Inclusion criteria
Patients must fulfil all the inclusion criteria and must 
not have any exclusion criteria to be eligible for 
randomisation.
1. Age at injury between 30 and 70 years.
2. Physical examination supports the diagnosis; for exam-
ple, a positive hip extension test, palpable defect and/
or local tenderness and haematoma.
3. MRI shows a complete acute avulsion of at least two of 
three tendons from the footprint at the ischial tuber-
osity.
4. Patient has a moderate to high activity level.
5. Patient has linguistic and mental ability to understand 
the rehabilitation programme explained in Swedish, 
Norwegian, Finnish or English.
6. Time from injury to inclusion in study is <4 weeks.
Exclusion criteria
1. Diabetes with secondary complications.
2. Previous major lower extremity injury or disease with 
sequelae.
3. Moderate or severe liver, pulmonary, kidney, psychiat-
ric or heart disease that significantly increases the risk 
of complications after operative treatment.
4. Severe obesity (Body Mass Index, BMI >35).
5. Alcohol or substance abuse.
6. High energy injury or combinations of injuries affect-
ing the lower extremity.
Intervention
We will randomly assign patients to either operative 
treatment (n=60) with suture anchor reinsertion of the 
tendons to the footprint at the ischial tuberosity or to 
non-operative treatment (n=60). Both groups will follow 
the same standardised rehabilitation protocol.
To minimise bias by indication, we will offer the patients 
who are eligible but where patient or doctor equipoise to 
treatment cannot be reached to participate in a parallel 
follow-up cohort with identical treatment options and 
follow-up. In the parallel cohort, the patients/surgeons 
preferred treatment is provided.
Surgical procedure
Patients allocated to the operative group will undergo 
surgery at the earliest convenient time but no later than 6 
weeks after the injury. The surgeon may choose whether 
to make a longitudinal or transversal skin incision. The 
proximal ends of the avulsed tendons are identified and 
after dissection they are reattached to the ischial tuber-
osity using at least two suture anchors. Data on the surgical 
approach, the number of suture anchors and their manu-
facturer as well as the surgeon’s intraoperative assessment 
of retraction and the number of tendons invovlved will 
be collected.
Rehabilitation
The rehabilitation protocol is based on a previously 
published rehabilitation protocol9 and will be the same 
for both treatment allocations. In brief, no brace is used. 
Full weight bearing is allowed. The patients are instructed 
to keep their stride length short, and to avoid sitting and 
any motion that stretches the hamstring for the first 
3 weeks. Patients are instructed to perform isometric 
exercises of the quadriceps and gluteal muscles to avoid 
muscle atrophy. After 2 weeks, isometric contractions 
of the hamstring muscles are allowed and progressed 
with cautious dynamic exercises during week 4. Specific 
hamstring strengthening exercises are begun after 
5 weeks.
Study outcomes
Primary outcome
The primary outcome measure will be the patient-re-
ported PHAT score6 at 24 months. PHAT is a condi-
tion-specific questionnaire with maximum score 100, with 
a higher score corresponding to higher function. The 
questionnaire uses a visual analogue scale for pain scores 
during different activities, as well as categorical scores for 
activity levels and tenderness, and has been shown to be 
sensitive to clinical changes.10
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Secondary outcomes
Additional patient-reported outcomes
The LEFS11 will be used to assess patient-reported 
outcome. LEFS is a reliable, valid and responsive tool 
for assessing functional status in several populations with 
lower extremity musculoskeletal conditions.11 12 Infor-
mation regarding physical activity level will be collected 
using the short form of International Physical Activity 
Questionnaire.13 14 Furthermore, data on general satisfac-
tion, return to work and return to sports will be collected.
Functional tests and muscle strength tests
The functional performance will be assessed through the 
timed step test,15 which is a test previously validated for 
knee arthroplasty patients and the single leg hop test, 
which is a performance-based test validated in anterior 
cruciate ligament trials.16 Measurement of maximum 
kinetic force (Newton, N) will be conducted using a 
handheld isometric dynamometer (microFET 2; Hoggan 
health industries).17 Study sites equipped with a comput-
er-based isokinetic dynamometer, Biodex,18 19 will assess 
peak torque (N) and total workload (Joule, J) of the 
hamstrings. All strength and functional performance tests 
will be reported with ratio of injured/uninjured leg, with 
the uninjured leg serving as reference for each subject.
Imaging outcomes
MRI will be used at 24 months to evaluate the entire thigh 
muscle volume and to assess muscle and tendon quality. 
We will use the uninjured side as reference for each 
subject.
data collection procedure
At inclusion demographic data activity at injury and time 
from injury to treatment is collected. Follow-up visits 
are planned at 3, 6, 12 and 24 months. A study nurse 
will provide a set of questionnaires for the patients to 
fill out. The nurse will also scan the patients’ charts for 
adverse events or complications. A physiotherapist that is 
blinded to the intervention will perform the strength and 
functional test at 6, 12 and 24 months. At the 24-month 
follow-up, MRI of both thighs will be performed.
Sample size
Taking into account the cost and risks associated with 
surgery, and the fact that the literature clearly recom-
mends surgery, a non-inferiority design was considered 
appropriate. Thus, the study aims to demonstrate that 
non-operative treatment is no worse than operative treat-
ment by more than the non-inferiority margin.
Based on the existing literature the SD of PHAT 
measurements is ~16–21.6 20 A reasonable non-inferiority 
margin is half of the SD and this effect size is lower than 
the minimal detectable change of the PHAT.6 To achieve 
85% power, with α=0.5, for demonstrating non-inferiority 
using a non-inferiority margin of 10, 50 patients in each 
arm are required. Heterogeneity of treatment effects is 
likely in surgical interventions and is best handled by 
increasing power. Some crossover and loss to follow-up 
will occur. For these reasons, we will continue inclusion 
until at least 60 patients in each group has initiated 
treatment.
randomisation procedure
The REDCap (REDCap Software) randomisation tool will 
be used to facilitate randomisation.21 Allocation tables 
with a random block size (2-6), stratified by study site, 
were created by a statistician and uploaded blinded into 
the REDCap project. The randomisation is permanent 
and not editable within the participant record and, like 
all other activity within REDCap, is tracked and not modi-
fiable in the audit log.
blinding
To minimise ascertainment bias this trial is single-blinded, 
where the physiotherapist conducting strength and func-
tional tests at 6, 12 and 24 months will be blinded to the 
intervention, by informing the patients not to tell and 
asking them to wear clothes concealing the surgery scar. 
The statistician analysing the data will also be blinded to 
treatment arms.
data management
All study data will be collected and managed in a digital 
case report form using REDCap electronic data capture 
tools hosted at Karolinska Institutet. REDCap is a 
secure, web-based application supporting data capture 
for research studies, providing: (1) an intuitive inter-
face for validated data entry; (2) audit trails for tracking 
data manipulation and export procedures; (3) auto-
mated export procedures for seamless data downloads 
to common statistical packages; and (4) procedures for 
importing data from external sources.21
Data will be kept securely in order to protect confi-
dentiality before, during and after the trial. A codebook 
matching the personal identification number and the 
trial identification number is kept at each study site and 
the trial identification number is noted in the patient’s 
electronic chart. The study nurses and investigators can 
log on and enter data directly into the database. Patients 
will complete surveys at each visit. Any paper forms used 
are stored for cross-checking at each study site.
Statistical analysis plan
The flow of patients through the trial is displayed in a 
Consolidated Standards of Reporting Trials diagram 
(figure 1). The number of patients screened for trial entry; 
those who are ineligible and the reasons why; number of 
eligible patients not providing consent; and the number 
of eligible patients subsequently randomised will be 
presented. The characteristics of the screened population, 
the ineligible participants and eligible participants who 
consent and do not consent will be summarised. Infor-
mation regarding the number of surgeons and centres, as 
well as number of patients treated by each surgeon will be 
provided. Data on patient eligibility and reasons for with-
drawal from treatment or the trial will be summarised. 
Baseline patient characteristics will be summarised using 
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Figure 1 Flowchart. This study illustrates the study design. 
IPAQ-SF, short form of International Physical Activity 
Questionnaire; LEFS, Lower Extremity Functional Scale; 
PHAT, Perth hamstring assessment tool. RCT, Randomised 
Controled Trial.
descriptive statistics; counts for categorical variables and 
mean/median and IQR for continuous variables.
Primary analyses will be by intention-to-treat (ITT). 
However, since ITT analyses can be anti-conservative for 
non-inferiority trials, we will also conduct perprotocol 
and as-treated analyses. Cases will only be considered 
treatment crossovers if the randomly assigned treat-
ment is changed by patient preferences. Non-operative 
treated patients who are treated operatively due to late 
complaints (>3 months after inclusion) will not be consid-
ered crossovers.
All analyses will be conducted blinded for treatment 
allocation. All statistical tests will be two-sided with an 
α of 0.05. Differences between groups in continuous 
skewed main outcome variables will be analysed by the 
Mann-Whitney U-test, and by the t-test when variables are 
from a symmetrical distribution. Results will be presented 
with 95% CIs. Two-way-tables with the χ2 test will be used 
for dichotomous variables. No adjustment of p values 
for multiple comparisons (secondary analyses) will be 
undertaken.
In secondary analyses, multivariate regression models 
will be used to analyse the primary outcome (PHAT 
score at 24-month follow-up). The main variables of 
interest included are the intervention, age, sex, study 
site and the degree of tendon retraction. We will also 
jointly analyse all timepoints in a linear mixed model 
(to adjust for within-patient correlations). Patients will 
be treated as a random effects, and time points, rando-
misation arm, age at baseline, sex and degree of tendon 
retraction will be included as fixed effects. As further 
secondary analyses, the randomised and observational 
cohorts will be analysed together using propensity 
scores adjustment (the randomised patients will get 
propensity score 0.5). The propensity score will be 
based on age, sex, study site, IPAQ and the degree of 
tendon retraction.
We will test for heterogeneity of treatment effects 
by testing for significant interactions in the following 
subgroups: tendon retraction >2 versus ≤2 cm and age >50 
versus ≤50 years.
Missing data can occur in two different ways in the 
study: (1) questions in the PHAT questionnaire can be left 
unanswered and (2) patients can miss specific follow-up 
visits or drop out of the study altogether. Missing PHAT 
score questions will be imputed based on the answered 
questions. Missed follow-up visit at 24 months will be 
handled using a multiple imputed model for the primary 
analysis. The multiple imputation protocol will be based 
on a longitudinal model for predicting PHAT at 24 
months based on the PHAT score recorded at previous 
time points together with patient age, sex and degree 
of tendon retraction. The mixed-effects model handles 
data missing at random seamlessly and no imputation 
will be needed for that specific analysis. We will test the 
robustness of the results to data not missing at random by 
assuming a missingness model where missingness is asso-
ciated with PHAT score.
Adverse events and complications
At follow-up, questions with the aim of identifying adverse 
events and serious adverse events will be provided. 
Medical records will also be checked for adverse effects. 
Undesired events such as surgical site infections, neuro-
logical sequelae, thromboembolism, rerupture or failure 
and hypertrophic scarring in surgical patients are defined 
as adverse effects. Serious adverse effects are defined as 
events resulting in death, hospitalisation or threatening 
life, that is, pulmonary embolism, sepsis or cardiovascular 
complications.
Patient and public involvement
Patients were not formally involved in designing the study 
protocol. In the process of designing the study protocol 
and selecting the primary outcome, a few patients were 
interviewed in clinical practice. Patients have been invited 
to participate in monitor meeting with researchers from 
the participating sites present. The participants will 
receive a written summary of main findings when the 
study is finished.
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Ethics and dissemination
The study will be conducted in agreement with the 
Helsinki declaration.
As both treatment options are accepted in the catch-
ment area for the study, the randomisation procedure 
was deemed ethically acceptable. The results will provide 
evidence-based treatment algorithms for future patients.
The primary study results will be submitted for publica-
tion to an international, peer-reviewed journal, regardless 
of whether the results are positive, negative or inconclu-
sive in relation to the study hypothesis.
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